NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported that its second-quarter revenues fell by 10 percent year over year, with much of that drop coming from an 8.4 percent negative impact from foreign currency translation.

The chemicals and lab products firm brought in revenues of $522 million for the three-month period ended June 30, compared to revenues of $580.7 million for the second quarter of 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.